Jeffrey Martens, Ph.D.




Thomas H. Maren Professor and Chair
Phone: 352-294-5352
Office: R5-234 Academic Research Bldg.
Website:  Martens’ Lab

Publications:  Search PubMed


Research Interests

Our laboratory is focused in two areas of Pharmacology and Therapeutics including Sensory Neuropharmacology and Cardiovascular Pharmacology with work in both the heart and olfactory systems.


In the olfactory system, our work is devoted to understanding mechanisms of olfaction, pathogenesis of olfactory dysfunction, and the development of curative therapies for anosmia. Olfactory dysfunction in the general population is frequent, affecting at least 2.5 million people in the U.S. alone.  In at least 20% of the cases the etiology of the chemosensory disturbance cannot be identified. We were one of the first to demonstrate olfactory dysfunction as a clinical manifestation of an emerging class of human genetic disorders, termed ciliopathies, which involve defects in ciliary assembly, maintenance, and/or function.  Importantly, we have demonstrated that gene therapy can be used to successfully rescue anosmia resulting from the malformation/loss of cilia. Projects in the laboratory seek to identify direct mechanisms by which sensory input and deprivation regulate olfactory function and how these are disrupted in disease states. Specifically we work to elucidate the mechanisms underlying the transport of odorant signaling proteins into cilia of olfactory sensory neurons and their alterations in cilia-related disorders. In addition work in the laboratory seeks to understand the importance of cilia for neurogenesis and cell differentiation, and their contribution to the regenerative properties of olfactory basal stem cells. Together, this work contributes to our understanding of the pathogenesis of human sensory perception diseases and paves the way for the development of treatments for olfactory loss in humans, where no curative therapies for ciliopathic disease exist.


In the cardiovascular system, projects in our laboratory are focused on the identification of novel targets for the treatment of cardiac arrhythmias. In particular, we are interested in therapies for atrial fibrillation, which is the most common cardiac arrhythmia affecting more than 2 million Americans. This electrical instability in the human heart can occur through a primary genetic defect in ion channel function or an acquired disorder attributable to ion channel dysregulation. We are interested in the regulation of voltage-gated potassium  (Kv) channels that are vital for atrial repolarization in the human heart. Work in our laboratory is devoted to understanding the details of Kv channel regulation, trafficking, and pharmacological modulation and how this is all integrated into the broader context of normal cardiomyocyte signaling and the pathogenesis of disease.